Boehringer Ingelheim introduces IDBS’ E-WorkBook Suite
28 October 2014 | By Boehringer Ingelheim
Global top 20 pharma company streamlines R&D IT with cross-domain platform...
List view / Grid view
News
Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
28 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and F-star Alpha Ltd. announced that the companies, together with the F-star Alpha Ltd. shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102...
SkyVision donates to The National Commission against Ebola in Guinea
28 October 2014 | By Distributed by APO (African Press Organization) on behalf of SkyVision Global Networks Ltd
The fund will be used to cover expenses and the needs of Ebola patients and affected families...
First patient included in phase ll study of BUPI, a novel topical formulation for treatment of oral pain
28 October 2014 | By Moberg Pharma
Moberg Pharma AB announced that the first patient has been included in a randomized controlled phase ll study with BUPI, a novel topical formulation for the treatment of oral pain...
France’s National Research Agency selects the OPTIVAC project and contributes €600,000 ($772,000) to improve the efficacy of influenza vaccines
27 October 2014 | By Imaxio
Imaxio announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'...
CHMP recommends label update for Esbriet in idiopathic pulmonary fibrosis, strengthening mortality benefit and reinforcing safety profile
27 October 2014 | By Roche
Roche announced that Esbriet® (pirfenidone) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an update to its European prescribing information, strengthening the efficacy claims and supporting the well-established safety profile based on the additional data from the phase III ASCEND trial...
Genticel: Business update – third quarter 2014
27 October 2014 | By Genticel
Genticel announces its net cash position and its highlights from the third quarter of 2014...
Frozen or Mighty Middle Management – the chilled pill for Pharma to swallow…
27 October 2014 | By AB Consulting
The Chief Executive of Valeant, the Canadian based speciality drugmaker recently commented that ‘the pharmaceutical industry is stuck in the 1980’s with big bureaucratic R&D functions that produce little value’...
Cancer drug first as Europe recommends approval of olaparib for women with BRCA-mutated ovarian cancer
27 October 2014 | By The Institute of Cancer Research
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA mutation - the first time a cancer drug has been approved targeted at an inherited genetic fault...
Europe approves novel Australian drug developed for rare sun disease
27 October 2014 | By Clinuvel Pharmaceuticals Limited
The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight...
Probiodrug raises €22.5 million in successful Initial Public Offering and listing on Euronext Amsterdam
24 October 2014 | By Probiodrug
Probiodrug AG announces the successful completion of its Initial Public Offering, which was launched on 10 October 2014 (the “IPO” or the “Offering”)...
Trial reported in Headache and Pain journal further confirms the effectiveness of electroCore’s non-invasive vagus nerve stimulation treatment for headache
24 October 2014 | By electroCore
Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore’s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes...
EMA ready to start assessment of Ebola vaccines and treatments as soon as data are made available
24 October 2014 | By European Medicines Agency
Rapid scientific advice to speed up development...
Results announcement for the third quarter 2014
24 October 2014 | By GlaxoSmithKline
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share...
Pharmaceutical industry feeling force of tax inversion legislation, says GlobalData Analyst
24 October 2014 | By GlobalData
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
